Biogen Idec has entered into a definitive license agreement with Trillium Therapeutics, granting exclusive worldwide rights to one of the company’s immune-based biologics development programmes.
Trillium CEO Dr Niclas Stiernholm said that Biogen Idec is a premier biotechnology partner and a world leader in immunology research and development.
Under the terms of the agreement, Trillium will receive an upfront payment and is eligible to receive milestone payments based on achievements of specified clinical, regulatory and commercial accomplishments. Trillium will also receive royalties on global product sales.
Biogen Idec will then be solely responsible for clinical development, regulatory approvals, manufacturing and commercialisation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData